Hologic, Inc. (NASDAQ:HOLX) Holdings Raised by Principal Financial Group Inc.

Principal Financial Group Inc. increased its position in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 3.6% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 269,546 shares of the medical equipment provider's stock after purchasing an additional 9,419 shares during the quarter. Principal Financial Group Inc. owned 0.12% of Hologic worth $21,957,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Cetera Investment Advisers lifted its position in shares of Hologic by 188.9% in the 1st quarter. Cetera Investment Advisers now owns 20,464 shares of the medical equipment provider's stock worth $1,595,000 after buying an additional 13,380 shares during the last quarter. Clearbridge Investments LLC boosted its stake in Hologic by 51.4% in the first quarter. Clearbridge Investments LLC now owns 518,596 shares of the medical equipment provider's stock valued at $40,430,000 after acquiring an additional 176,006 shares during the period. Andra AP fonden boosted its stake in Hologic by 224.5% in the second quarter. Andra AP fonden now owns 95,400 shares of the medical equipment provider's stock valued at $7,083,000 after acquiring an additional 66,000 shares during the period. Swedbank AB grew its holdings in shares of Hologic by 5.2% during the second quarter. Swedbank AB now owns 1,630,440 shares of the medical equipment provider's stock valued at $121,060,000 after purchasing an additional 80,575 shares during the last quarter. Finally, National Bank of Canada FI raised its position in shares of Hologic by 352.0% during the 1st quarter. National Bank of Canada FI now owns 299,098 shares of the medical equipment provider's stock worth $22,474,000 after purchasing an additional 232,928 shares during the period. Institutional investors and hedge funds own 94.73% of the company's stock.

Hologic Price Performance

Shares of HOLX stock traded down $1.20 during mid-day trading on Thursday, hitting $77.98. 679,844 shares of the stock traded hands, compared to its average volume of 1,588,434. Hologic, Inc. has a twelve month low of $67.59 and a twelve month high of $84.67. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.03 and a current ratio of 3.69. The company's 50-day simple moving average is $80.84 and its 200-day simple moving average is $78.22. The firm has a market cap of $18.11 billion, a price-to-earnings ratio of 23.78, a price-to-earnings-growth ratio of 2.52 and a beta of 0.98.

Hologic (NASDAQ:HOLX - Get Free Report) last released its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $1.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The firm had revenue of $987.90 million for the quarter, compared to analyst estimates of $978.25 million. During the same period in the previous year, the company earned $0.89 earnings per share. Hologic's revenue was up 4.5% compared to the same quarter last year. As a group, equities research analysts expect that Hologic, Inc. will post 4.27 earnings per share for the current year.

Wall Street Analyst Weigh In

HOLX has been the subject of a number of recent research reports. Needham & Company LLC restated a "buy" rating and set a $90.00 price objective on shares of Hologic in a research note on Tuesday, October 15th. Royal Bank of Canada increased their price objective on shares of Hologic from $86.00 to $89.00 and gave the stock a "sector perform" rating in a report on Tuesday, November 5th. Stephens reissued an "overweight" rating and set a $92.00 target price on shares of Hologic in a research note on Tuesday, July 30th. Citigroup lowered shares of Hologic from a "buy" rating to a "neutral" rating and dropped their price target for the company from $95.00 to $85.00 in a research note on Tuesday, October 1st. Finally, Raymond James boosted their price objective on Hologic from $93.00 to $95.00 and gave the stock an "outperform" rating in a research report on Tuesday, November 5th. Four analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $89.91.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.